JP5746196B2 - Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 - Google Patents
Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 Download PDFInfo
- Publication number
- JP5746196B2 JP5746196B2 JP2012534798A JP2012534798A JP5746196B2 JP 5746196 B2 JP5746196 B2 JP 5746196B2 JP 2012534798 A JP2012534798 A JP 2012534798A JP 2012534798 A JP2012534798 A JP 2012534798A JP 5746196 B2 JP5746196 B2 JP 5746196B2
- Authority
- JP
- Japan
- Prior art keywords
- hiv infection
- therapeutic agent
- inhibitor
- hiv
- infection according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BBTXLOZXLJRPEK-UHFFFAOYSA-N CC(Nc(cc1)ccc1C(NO)=O)=O Chemical compound CC(Nc(cc1)ccc1C(NO)=O)=O BBTXLOZXLJRPEK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI2009A001837A IT1396915B1 (it) | 2009-10-23 | 2009-10-23 | Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv. |
| ITMI2009A001837 | 2009-10-23 | ||
| PCT/IB2010/054139 WO2011048514A1 (en) | 2009-10-23 | 2010-09-14 | Derivatives of n-hydroxybenzamide for treating hiv infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013508349A JP2013508349A (ja) | 2013-03-07 |
| JP2013508349A5 JP2013508349A5 (enExample) | 2013-05-09 |
| JP5746196B2 true JP5746196B2 (ja) | 2015-07-08 |
Family
ID=42153811
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534798A Expired - Fee Related JP5746196B2 (ja) | 2009-10-23 | 2010-09-14 | Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8637702B2 (enExample) |
| EP (1) | EP2490682A1 (enExample) |
| JP (1) | JP5746196B2 (enExample) |
| KR (1) | KR101687644B1 (enExample) |
| CN (1) | CN102548551A (enExample) |
| BR (1) | BR112012008780A2 (enExample) |
| CA (1) | CA2773210C (enExample) |
| IN (1) | IN2012DN03387A (enExample) |
| IT (1) | IT1396915B1 (enExample) |
| WO (1) | WO2011048514A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9345905B2 (en) * | 2011-11-29 | 2016-05-24 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents |
| MX349767B (es) | 2012-02-03 | 2017-08-11 | Italfarmaco Spa | Cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil) -naftalen-2-il-metil]-amonio para su uso en el tratamiento de distrofia muscular. |
| IT201600074606A1 (it) * | 2016-07-18 | 2018-01-18 | Italfarmaco Spa | New benzo-N-hydroxy amide compounds having antitumor activity |
| WO2018075564A1 (en) | 2016-10-17 | 2018-04-26 | University Of Maryland, College Park | Multispecific antibodies targeting human immunodeficiency virus and methods of using the same |
| IT201900003281A1 (it) * | 2019-03-06 | 2020-09-06 | Chemi Spa | Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza |
| WO2022088047A1 (zh) * | 2020-10-30 | 2022-05-05 | 中国科学院深圳先进技术研究院 | Itf2357在制备预防和治疗冠状病毒的药物中的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1283637B1 (it) | 1996-05-14 | 1998-04-23 | Italfarmaco Spa | Composti ad attivita' antinfiammatoria ed immunosoppressiva |
| ITMI20030025A1 (it) | 2003-01-10 | 2004-07-11 | Italfarmaco Spa | Derivati dell'acido idrossammico ad attivita' antinfiammatoria. |
| ITMI20030063A1 (it) | 2003-01-17 | 2004-07-18 | Italfarmaco Spa | Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico. |
| AU2005223659A1 (en) * | 2004-03-18 | 2005-09-29 | Georgetown University | Benzamide and benzoate anti-HIV compounds |
| ITMI20041347A1 (it) * | 2004-07-05 | 2004-10-05 | Italfarmaco Spa | Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria |
| WO2008097654A1 (en) | 2007-02-08 | 2008-08-14 | Merck & Co., Inc. | Methods of using saha for treating hiv infection |
-
2009
- 2009-10-23 IT ITMI2009A001837A patent/IT1396915B1/it active
-
2010
- 2010-09-14 JP JP2012534798A patent/JP5746196B2/ja not_active Expired - Fee Related
- 2010-09-14 KR KR1020127007623A patent/KR101687644B1/ko not_active Expired - Fee Related
- 2010-09-14 IN IN3387DEN2012 patent/IN2012DN03387A/en unknown
- 2010-09-14 US US13/393,863 patent/US8637702B2/en active Active
- 2010-09-14 CA CA2773210A patent/CA2773210C/en not_active Expired - Fee Related
- 2010-09-14 EP EP10771187A patent/EP2490682A1/en not_active Withdrawn
- 2010-09-14 BR BR112012008780-0A patent/BR112012008780A2/pt not_active Application Discontinuation
- 2010-09-14 WO PCT/IB2010/054139 patent/WO2011048514A1/en not_active Ceased
- 2010-09-14 CN CN2010800454818A patent/CN102548551A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20091837A1 (it) | 2011-04-23 |
| CN102548551A (zh) | 2012-07-04 |
| EP2490682A1 (en) | 2012-08-29 |
| IN2012DN03387A (enExample) | 2015-10-23 |
| CA2773210C (en) | 2017-01-03 |
| IT1396915B1 (it) | 2012-12-20 |
| US20120203014A1 (en) | 2012-08-09 |
| KR20120083356A (ko) | 2012-07-25 |
| BR112012008780A2 (pt) | 2020-12-01 |
| KR101687644B1 (ko) | 2016-12-19 |
| JP2013508349A (ja) | 2013-03-07 |
| CA2773210A1 (en) | 2011-04-28 |
| WO2011048514A1 (en) | 2011-04-28 |
| US8637702B2 (en) | 2014-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12083119B2 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| JP5746196B2 (ja) | Ｈｉｖ感染症を治療するためのｎ−ヒドロキシベンズアミドの誘導体 | |
| US8247613B2 (en) | Methods and compositions for the synergistic activation of latent HIV | |
| US20060009527A1 (en) | Method of treating TRX mediated diseases | |
| US20210060014A1 (en) | Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors | |
| JP2016536354A (ja) | 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｂｔｋ阻害剤との組み合わせ | |
| US20100324034A1 (en) | Methods of Using SAHA for Treating HIV Infection | |
| US10184933B2 (en) | Compositions, systems and methods for gene expression noise drug screening and uses thereof | |
| RU2009120115A (ru) | Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом | |
| US20170348295A1 (en) | Small molecule inhibitors of viral protein interactions with human t-rna | |
| US20150343011A1 (en) | Treatment Of HIV-1 Infection And AIDS | |
| JP2020536890A (ja) | 癌を治療するためのｍｄｍ２阻害剤とｅｒｋの阻害剤との組合せ | |
| US10633363B2 (en) | EPAC1 activators as HIV latency reversal agents (LRA) | |
| US11554123B2 (en) | Compositions and methods for reactivating latent HIV-1 infections | |
| AU2005227400B2 (en) | Method of Treating TRX Mediated Diseases | |
| AU2008202913A1 (en) | Method of Treating TRX Mediated Diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130319 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140715 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141010 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150407 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5746196 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |